News and Trends 6 Jan 2020 €5M Investment to Fund French Biotech’s Resistance-Busting Antibiotic Mutabilis has received a €5M investment from the Danish VC Novo Holdings’ REPAIR Impact Fund to fuel the development of a new class of antibiotics that could kill drug-resistant strains of gram-negative bacteria. The French company will use the money to advance one of its preclinical drugs, a wide-spectrum intravenous antibiotic, to clinical trials. The […] January 6, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 11 Dec 2019 Collaboration Between Founders and Investors Primes Biotech Startups for Success How can entrepreneurs work with investors to maximize the chances of their company succeeding? Venture capital partner Nanna Lüneborg and biotech entrepreneur Mai-Britt Zocca spoke at Labiotech Refresh in Copenhagen about their experiences in founding IO Biotech, a Danish biotech startup that develops cancer immunotherapies. Zocca and Lüneborg were both involved in setting up IO […] December 11, 2019 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2019 €20M Series A Launches Cancer Immunotherapy Biotech in Denmark The Danish company STipe Therapeutics has been launched with a €20M Series A to develop immunotherapy drugs that sensitize the innate immune system against cancer. STipe Therapeutics was spun out from Aarhus University, Denmark, last year with a small grant, and has now completed its full launch with this Series A. The round was co-led […] September 30, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Sep 2019 Danish Smallpox Vaccine Gets FDA Approval to Fight Bioterrorism A vaccine developed by the Danish company Bavarian Nordic has received FDA approval to prevent infections by monkeypox, as well as protect against the threat of a smallpox bioterror attack. This approval makes Bavarian Nordic’s vaccine the only approved vaccine in the world for preventing monkeypox, a rare viral infection that is similar to smallpox […] September 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2019 First Potential Chlamydia Vaccine Shows Early Promise A vaccine targeting the sexually transmitted infection chlamydia, which would be the first of its kind if approved, has proved safe and able to stimulate the immune system in a phase I trial. In the phase I trial, the vaccine was injected into 35 healthy women. Blood samples from the volunteers were then measured to […] August 16, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2019 Joint Venture First to Offer Seamless Manufacturing of Microbiome Therapies Lonza, a Swiss pharma supplier, and Chr. Hansen, a Danish supplier of bacterial products, are teaming up to enter the promising microbiome space. Together, the two companies will invest €90M in the creation of the first company that will offer a full supply chain to produce treatments made of live bacteria. Their 50/50 joint venture […] April 3, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Mar 2019 Danish Startup Gets €5.5M to Produce Hard-to-Make Chemicals Through Fermentation CysBio is developing a fermentation technology to produce valuable chemicals that were previously too difficult or expensive to make. Founded just at the beginning of this year, CysBio is now receiving its first funding. This seed investment comes from the Chinese chemical company Zhejiang NHU, which has also established a partnership to commercialize some of […] March 22, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Feb 2019 Anti-CRISPR Proteins Could Improve Gene Editing Precision A research group in Denmark has found proteins in gut and soil microbes that can inhibit the action of CRISPR-Cas9 gene editing, a finding that could help to control the technology with more precision and less risk. Bacteria and viruses have fought an evolutionary arms race for millions of years. Bacteria evolved CRISPR systems to […] February 8, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2019 Danish Biotech’s Drug for Rare Metabolic Disease Aces Clinical Trial A drug, developed by the Danish biotech Orphazyme for a rare metabolic disease, has shown promising results in a phase II/III trial, reducing the disease’s progression by 74%. The 50 patients recruited into the trial suffered from Niemann-Pick disease type C, a metabolic disease in which proteins crucial for storing fat molecules such as cholesterol […] January 30, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jan 2019 Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after the US District Court of Delaware declared three of its cancer immunotherapy patents invalid. MorphoSys began the dispute over Darzalex (daratumumab), Genmab and Janssen’s approved antibody therapy for the blood cancer multiple myeloma. MorphoSys alleged that Darzalex infringed on three of […] January 28, 2019 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
More News! 21 Jan 2019 Danish Biotech Turns Bacteria into Fermentation Workaholics The Danish biotech Enduro Genetics has shown it can improve the yield of fermentation by engineering bacteria to become ‘addicted’ to being productive. Fermentation vats full of bacteria or yeast are the workhorses for industries such as the pharmaceutical and chemical industry. They are used to mass-produce products including detergents, drugs and biofuels. The cells […] January 21, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 14 Dec 2018 This Company is Strengthening Muscles in Neuromuscular Disorders NMD Pharma, our pick of this week, is based in Aarhus, Denmark. The company is flexing its muscles to develop a drug that can treat muscle weakness in orphan neuromuscular disorders such as amyotrophic lateral sclerosis and myasthenia gravis. Mission: To develop drugs to counteract muscle weakness in incurable neuromuscular disorders. Neuromuscular disorders come […] December 14, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email